An interventional study of LLM-Generated Plain-Language Patient Synopsis in Hematologic Neoplasms and Oncologic Disorders, sponsored by Technical University of Munich. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-16.
Sponsored by Technical University of Munich · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Hematologic Neoplasms with a site in Germany — 20 open to participants now, 28 under way, 3 of them phase 3. Hematologic Neoplasms · Germany.
Among the 65 studies in Hematologic Neoplasms with a site in Germany, this one is the 17th largest by planned enrollment of the 50 interventional ones that give a count, is one of 4 that started in 2026, is one of 5 with no phase, reaches primary completion later than 6 of the 27 other live ones, and was the 63rd registered.
1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.
Browse Hematologic Neoplasms studies →20 of the 65 studies in Hematologic Neoplasms with a site in Germany are open now. Recruiting first, the newest first:
Technical University of Munich · Sites in Germany
CSL Behring · Sites in Germany, United States, Belgium and 8 more countries
Ages 18+
Kura Oncology, Inc. · Sites in Germany, United States, Australia and 14 more countries
Ages 18+
Swedish Orphan Biovitrum · Sites in Germany, United States, Canada and 5 more countries
Ages 18+
University Hospital Tuebingen · Sites in Germany
Ages 8 wk–65 yrs
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 25 · Phase 3 13
First in 1995; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 46 across 1,047 interventional studies indexed under Hematologic Neoplasms.
Median enrollment 91 across the 50 interventional studies, 450 across the 15 observational. Of the 32 that completed or were terminated, 14 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 65 have an industry lead sponsor. The 10 most frequent:
Technical University of Munich is the lead sponsor of 323 studies on the registry; 61 are open to participants now.
Technical University of Munich has 3 studies filed under Hematologic Neoplasms — fewer than ten, so there is no comparison to draw.
9 of the studies in Hematologic Neoplasms with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07519811Technical University of MunichLLM-Generated Plain-Language Patient Synopses to Improve Comprehension in Hematology and Oncology (oncOPAL) | 2026-12-31 |
| NCT03735992Universität Duisburg-EssenMind-body Medicine for Patients With Malignant Hematological Diseases | 2026-12-31 |
| NCT07939139Technical University of MunichShadow-Mode Evaluation of an AI Assistant for Multidisciplinary Tumor Boards | 2027-01-31 |
| NCT06645886Kumquat Biosciences Inc.A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies | 2027-03 |
| NCT05502887Prof. Dr. Thomas LuftThe Endothelial Cell Dysfunction and Outcome Project for Hematological Neoplasms | 2027-06-07 |
Add all 9 to your calendar (.ics) → With an account.
Among the 65 studies in Hematologic Neoplasms with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study tests whether patients with blood cancer or other cancers better understand their medical information when it is rewritten in plain language by an artificial intelligence (AI) system.
When patients are discharged from the hospital, they receive a medical letter summarizing their diagnosis, treatment, and next steps. These letters are often written in technical language that is difficult for patients to understand. In this study, an AI language model running on the hospital's own secure servers rewrites parts of this letter into simpler language. A physician checks the simplified version before the patient receives it.
Patients are randomly assigned to one of two groups. One group receives both the standard medical letter and the AI-simplified version. The other group receives the standard letter only. A separate group of patients who do not speak German well will receive a simplified and translated version.
After reading their letter, all participants fill out a short questionnaire about how well they understood the information. The study takes place at TUM University Hospital (Klinikum rechts der Isar) in Munich, Germany.
Background:
Studies show that up to 40-80% of medical information conveyed during physician consultations is not correctly recalled or understood by patients. This problem is particularly relevant in hematology and oncology, where treatment regimens, prognoses, and side-effect profiles are complex. Large language models (LLMs) have demonstrated the ability to convert medical texts into plain language with high accuracy. However, prospective randomized controlled trials evaluating the clinical benefit of LLM-simplified patient synopses in routine care are lacking.
Study Design:
Prospective, single-center, randomized controlled trial with parallel group design. Randomization is 2:1 (intervention : control) using permuted blocks of variable size (4-6). An additional non-randomized translation arm enrolls patients with insufficient German language proficiency.
Intervention:
The locally implemented LLM system (on-premise, no external data transmission) automatically simplifies the following sections of the discharge letter: Current Status, Medical History, Epicrisis, and Further Management. A study physician reviews and approves the simplified version before it is given to the patient. The system is not classified as a medical device and is not used for diagnosis or treatment decisions.
Endpoints:
The primary endpoint is a comprehension score measured by a 5-item scale (10-point Likert, based on PEMAT), assessing overall comprehension and comprehension of diagnosis, treatment, next steps, and medical terminology. Secondary endpoints include patient satisfaction (EORTC QLQ-INFO25 subscales), subjective uncertainty reduction, format preference, physician review time, correction rate, and translation quality.
Statistical Analysis:
The primary endpoint will be analyzed using a t-test or Mann-Whitney U-test. A clinically relevant difference of 1.5 points on the 10-point scale is assumed. With a standard deviation of 2.5, power of 80%, and alpha of 0.05 (two-sided), 136 randomized patients are required (91 intervention, 45 control). Accounting for a 10% dropout rate, 150 patients will be recruited for the randomized arms, plus 30 for the translation arm (total n=180).
Data Protection:
All data are pseudonymized and stored on secure hospital servers. No patient data are transmitted to external servers or cloud services. The study complies with GDPR.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive the standard discharge letter synopsis plus an LLM-generated plain-language version of the following sections: Current Status, Medical History, Epicrisis, and Further Management. The simplified version is reviewed and approved by a study physician before being given to the patient.
Other: LLM-Generated Plain-Language Patient Synopsis
Participants receive the standard discharge letter synopsis only, as provided in routine clinical care.
A locally implemented large language model (GPT-OSS, on-premise) automatically rewrites selected sections of the hospital discharge letter (Current Status, Medical History, Epicrisis, and Further Management) into plain language. A study physician reviews the output for accuracy before it is provided to the patient. The system is not classified as a medical device and is not used for diagnosis or treatment decisions. No patient data are transmitted to external servers.
Patient Comprehension Score
Comprehension of the patient synopsis measured using a 5-item scale based on the Patient Education Materials Assessment Tool (PEMAT; scores range from 1 to 10, with higher scores indicating better comprehension), assessing overall comprehension and comprehension of diagnosis, treatment, next steps, and medical terminology. The score is calculated as the mean of all five items (range 0-10; higher scores indicate better comprehension).
Time frame: At the time of hospital discharge (Day 0), assessed immediately after reading the synopsis (approximately 15-30 minutes after receipt)
Patient Satisfaction with Information Received
Patient satisfaction (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Information Module 25 \[EORTC QLQ-INFO25\] subscales; scores range from 0 to 100, with higher scores indicating better-perceived information)
Time frame: Day 0, assessed immediately after reading the synopsis
Subjective Uncertainty Reduction
Single-item measure on a 0-10 scale, administered before and after reading the synopsis
Time frame: Day 0, before and after reading the synopsis
Patient Preference for Synopsis Format
Categorical variable assessing which synopsis format the patient preferred
Time frame: Day 0, assessed immediately after reading the synopsis
Physician Review Time
Time in minutes required for the study physician to review and approve the LLM-generated synopsis
Time frame: Day 0, recorded at time of physician review
Physician Correction Rate
Rate of necessary corrections made by the study physician to the LLM-generated synopsis prior to patient handout
Time frame: Day 0, recorded at time of physician review
Plan to share: No — Individual participant data will not be shared. All study data are pseudonymized and stored on secure hospital servers at TUM University Hospital (Klinikum rechts der Isar) in compliance with the General Data Protection Regulation (GDPR). The study protocol does not provide for disclosure of participant-level data to third parties. Aggregate, anonymized data will be made available through publication of results.
Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.
Of 186 non-industry interventional studies with no phase under Hematologic Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 125. This study's planned 8 months is below that.
Counting every sponsor, half of 192 studies reached it within 40 months; a quarter within 21 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Technical University of Munich →